Because the ligand binding–defective mutant is expressed in only approximately 30% of the healthy human population but enriched up to ~70%–80% in all carcinomas and ~64% in CRCs (8) (Figure 1B), we hypothesized that the minority of humans who express full-length Siglec-XII may be at the highest risk for developing advanced carcinomas. This evidence concerns the gene SIGLEC12 and carcinoma.